SANTA CLARA, Calif.–(EON: Enhanced Online News)–Crown Bioscience, Inc.,
a preclinical oncology CRO, announced today that Dr. Chuan (Joe) Shih has
accepted the position of Executive Vice President, Integrated Drug Discovery
Services Business Unit.
“DR. SHIH IS WIDELY REGARDED AS ONE OF THE INDUSTRY’S LEADING EXPERTS IN
ONCOLOGY DRUG DISCOVERY AND DEVELOPMENT. HE WILL BRING A UNIQUE
PERSPECTIVE TO THE COMPANY AS WE CONTINUE TO IDENTIFY NEW OPPORTUNITIES
THAT HELP OUR CLIENTS ACCELERATE THEIR DRUG DISCOVERY AND DEVELOPMENT
PROGRAMS”
Prior to joining Crown, Dr. Joe Shih, Ph.D., was a Distinguished Lilly Scholar of
Discovery Chemistry Research and Technology at Lilly Research Laboratories
(LRL), a Division of Eli Lilly and Company. Joe received a doctorate in Organic
Chemistry from The Ohio State University in 1982. He was also awarded a
Bachelor of Science in Chemistry from the National Chung-Hsing University,
Taiwan in 1976, and a Master of Science in Organic Chemistry from The Ohio
State University in 1979. Dr. Shih completed a postdoctoral fellowship at Harvard
University under Nobel Laureate Professor E. J. Corey from 1982 to 1984.
Following his postdoctoral studies, he joined Lilly as a Senior Organic Chemist in
1984. He was promoted to Research Scientist in 1989, to Senior Research Scientist
in 1993, to Research Advisor in 1999, to Distinguished Research Fellow in 2004
and to Distinguished Lilly Scholarin 2007.
During his tenure at Eli Lilly, Dr. Shih has distinguished himself as a premier
drug hunter by contributing to many LRL oncology drug discovery efforts.
Through his collaboration with Princeton University, Dr. Shih contributed to the
successful antifolate drug discovery program that has led to the development of
ALIMTA®, a blockbuster anticancer agent approved by various regulatory
agencies around the globe for the treatment of mesothelioma and non-small cell
lung cancer. Dr Shih is a co-inventor of ALIMTA® and a pioneerin the elucidation
of the unique “multi-targeted antifolate” mechanism of action of ALIMTA®. Dr.
Shih was awarded the 2006 American Chemical Society “Heroes of Chemistry”. Award for his role in the discovery and development of ALIMTA®.
Dr. Shih was also instrumental in leading various medicinal chemistry and drug discovery initiatives and efforts in the identification of several novel anticancer
agents currently in the Lilly Oncology pipeline. Dr. Shih is widely recognized for
his expertise in cancer and medicinal chemistry research. He is frequently invited
to lecture and chair sessions at national and international meetings. Dr. Shih has
authored and co-authored more than 180 scientific publications and presentations
and holds numerous patents. Dr. Shih is also holding a position of visiting
Distinguished Chair Professor of Pharmaceutical Sciences at the Department of
Applied Biology and Chemical Technology of The Hong Kong Polytechnic
University.
“Dr. Shih is widely regarded as one of the industry’s leading experts in oncology
drug discovery and development. He will bring a unique perspective to the
company as we continue to identify new opportunities that help our clients
accelerate their drug discovery and development programs,” said Alex Wu, Chief
Executive Officer of CrownBio.
“CrownBio’s reputation for scientific and service excellence, consistent quality
and commitment to supporting the discovery of anti-tumor therapeutics is
unparalleled in the industry,” said Dr. Shih. “I look forward to working with this
truly talented team as well as playing a role in the Company’s growth.”
About Crown Bioscience,Inc.
Crown Bioscience, Inc. is a U.S.-based drug discovery service company with R&D
facilities in China committed to advancing anti-cancer therapeutics through the
preclinical and drug development stages. Its proprietary CrystalClear™,
HuPrime™ and HuKemia™ platforms enable unique lead optimization and
translational oncology strategies to deliver better clinical candidates. Our team of
experts provides an integrated service solution from idea to IND, including:
preclinical, translational, and clinical capabilities.
